Pharma BD Deal Intelligence
Became the seed asset for Nestlé Health Science, but no public evidence the $2.5B price paid off on its own economics; culture-clash integration was documented as a real, non-trivial problem.
Full analysis, sources & comparables →Nestle agreed to buy Novartis Medical Nutrition for $2.5B, strengthening its #2 position behind Abbott in clinical nutrition and continuing its push into…
Nestle confirmed the US$2.5bn purchase of Novartis Medical Nutrition, covering oral and tube-delivery nutritional supplements for hospitals and nursing homes;…
Nestle completed the $2.5B acquisition on July 2, 2007 after EU regulatory review, elevating it to a 'very strong player in the strategic core category of…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Nestle SA acquired Novartis Medical Nutrition for approximately $2.5 billion (announced December 2006, completed July 2007 following regulatory review), adding the Optifast, Boost and Resource clinical-nutrition brands — a unit generating roughly $950 million in annual sales — and making Nestle the world's number-two player in healthcare nutrition behind Abbott. The divestiture allowed Novartis to refocus on its core pharmaceuticals business. Note: this is a medical-nutrition transaction, borderline relative to core pharma.
Became the seed asset for Nestlé Health Science, but no public evidence the $2.5B price paid off on its own economics; culture-clash integration was documented as a real, non-trivial problem.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Nestle SA / Novartis Medical Nutrition (this deal) | 2006 | $2.5B | 64 |
| Nestle SA / Pfizer Nutrition (Pfizer Inc. infant nutrition unit) | 2012 | $11.8B | 50 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Crucell N.V. / Berna Biotech AG | 2006 | $450M | 85 |
| Lonza Group AG / Cambrex Bioproducts and Biopharma businesses | 2006 | $460M | 83 |
| Reckitt Benckiser plc / Boots Healthcare International | 2006 | $3.4B | 82 |
| Genentech, Inc. (Roche Group) / Tanox Inc. | 2006 | $919M | 80 |
← Browse all deals · How we score deals
More: 2006 deals